{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:35:36Z","timestamp":1790786136084,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Abrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1239869","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:06:15Z","timestamp":1693555575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series"],"prefix":"10.3389","volume":"10","author":[{"given":"Bingyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2147\/CCID.S392280","article-title":"Tofacitinib for the treatment of steroid-induced rosacea","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/0019-5154.77547","article-title":"Steroid-induced rosacea: a clinical study of 200 patients","volume":"56","author":"Bhat","year":"2011","journal-title":"Indian J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8385","DOI":"10.3892\/mmr.2018.8887","article-title":"The therapeutic effect of artesunate on rosacea through the inhibition of the JAK\/STAT signaling pathway","volume":"17","author":"Li","year":"2018","journal-title":"Mol Med Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/jid.2008.237","article-title":"Glucocorticoids enhance toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines","volume":"129","author":"Shibata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.det.2017.11.001","article-title":"Rosacea pathogenesis","volume":"36","author":"Ahn","year":"2018","journal-title":"Dermatol Clin"},{"key":"ref6","first-page":"198","article-title":"Steroid-induced rosacealike dermatitis: case report and review of the literature","volume":"83","author":"Chen","year":"2009","journal-title":"Cutis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/icb.2014.51","article-title":"STAT1 plays a role in TLR signal transduction and inflammatory responses","volume":"92","author":"Luu","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2147\/DDDT.S240866","article-title":"The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: a short report of the clinical data","volume":"15","author":"Napolitano","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e15214","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e15524","DOI":"10.1111\/dth.15524","article-title":"Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0021-9258(17)30282-X","article-title":"Conformation of functionally homologous proteins. Turtle and bovine ribonucleases","volume":"254","author":"Myer","year":"1979","journal-title":"J Biol Chem"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.3390\/jcm12082865","article-title":"The use of JAK\/STAT inhibitors in chronic inflammatory disorders","volume":"12","author":"Caiazzo","year":"2023","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/medicina59040801","article-title":"Hidradenitis suppurativa and JAK inhibitors: a review of the published literature","volume":"59","author":"Martora","year":"2023","journal-title":"Medicina"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e15848","DOI":"10.1111\/dth.15848","article-title":"Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series","volume":"35","author":"Sun","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1239869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:06:18Z","timestamp":1693555578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1239869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":18,"alternative-id":["10.3389\/fmed.2023.1239869"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1239869","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"1239869"}}